查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1598699

结核病诊断市场：按测试类型、类型和最终用户 - 2025-2030 年全球预测

Tuberculosis Diagnostics Market by Test Type (Drug-susceptibility Testing, Laboratory Methods, Mantoux Test), Type (Point-of-Care Technologies, Rapid Test), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年结核病诊断市值为30.1亿美元，预计到2024年将达到31.7亿美元，复合年增长率为5.48%，到2030年将达到43.8亿美元。

结核病诊断的范围包括旨在识别结核分枝病菌感染的各种测试和程序。这包括痰液显微镜检查、培养等传统方法和核酸增幅检查(NAAT) 等新型分子诊断方法。结核病是感染疾病导致死亡的主要原因，全球的结核病负担强调了有效结核病诊断的必要性。其应用范围广泛，从早期诊断和治疗反应监测到药物敏感性测试。最终用途包括医院、诊断实验室和研究机构，强调临床和公共卫生观点。

主要市场统计
基准年[2023] 30.1亿美元
预测年份 [2024] 31.7亿美元
预测年份 [2030] 43.8亿美元
复合年增长率（%） 5.48%

根据市场洞察，技术进步、结核病患者病率上升以及医疗基础设施改善是成长的主要动力。特别是，与传统方法相比，更高的准确性和更快的结果促进了向分子诊断的快速过渡。潜在的商机存在于结核病患者病率较高但诊断设施有限的新兴国家。在那里，我们可以透过与政府健康和卫生倡议的合作来扩大市场。然而，主要挑战包括先进诊断的高昂成本、结核病细菌类型的准确性差异以及低收入地区的认识较低。

创新领域包括开发具有成本效益的照护现场诊断工具，以提供快速可靠的结果。这些有可能彻底改变结核病诊断，特别是在农村和资源有限的环境中。此外，研究检测抗药性结核分枝桿菌的方法可能会在对抗多重抗药性结核病的斗争中取得重大突破。

由于国内外参与者众多，该市场呈现分散性，企业可以透过投资产品差异化和策略联盟来取得成功。与非政府组织和公共卫生计画的合作可以增强市场渗透和推广工作。识别这些驱动因素并透过有针对性的研究和策略规划解决限制将导致结核病诊断市场的持续成长。

市场动态：揭示快速发展的结核病诊断市场的关键市场洞察

结核病诊断药物市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球结核病负担日益增加以及早期诊断的必要性
    • 研发投入增加，诊断产品集中化
    • 政府支持措施和新兴市场意识的提高
  • 市场限制因素
    • 结核病诊断药物的高成本
    • 有限的兑换选项
  • 市场机会
    • 加强政府意识计划
    • 诊断方法的进展
  • 市场挑战
    • 新兴市场的覆盖率低或没有保险

波特五力策略工具引领结核病诊断市场

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对结核病诊断药物市场的影响

外部宏观环境因素在塑造结核病诊断市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助企业预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解结核病诊断药物市场的竞争状况

对结核病诊断市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 结核病诊断市场中的定位矩阵供应商绩效评估

FPNV定位矩阵是评估结核病诊断市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议，描绘结核病诊断市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，结核病诊断市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球结核病负担不断增加，增加了早期诊断的需求。
      • 增加研发投资和研发中的密集诊断产品
      • 政府的支持努力和新兴市场意识的提高
    • 抑制因素
      • 结核病诊断药物的高成本
      • 退款选项有限
    • 机会
      • 加强政府意识计划
      • 诊断程序的进展
    • 任务
      • 新兴市场的保险覆盖率低或没有
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章结核病诊断市场：依测试类型

  • 药敏试验
  • 实验方法
  • 曼图测试
  • 核酸检测
  • 射线照相

第七章结核病诊断药物市场：依类型

  • 照护现场技术
  • 快速测试

第八章结核病诊断市场：依最终用户分类

  • 诊断研究室
  • 医院/诊所

第九章北美和南美结核诊断药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太结核病诊断药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第11章：欧洲、中东和非洲的结核病诊断药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • ACON Laboratories, Inc.
  • Becton, Dickinson, and Company
  • bioMerieux SA
  • Bruker Corporation
  • Cepheid
  • Elisabeth Pharmacon, spol. s ro
  • ELITech Group
  • F. Hoffmann-La Roche AG
  • Hologic Corporation
  • OSANG HEALTHCARE CO., LTD
  • PerkinElmer, Inc.
  • Siemens AG
  • Thermo Fisher Scientific, Inc.
  • Turklab AS
Product Code: MRR-03252A5F9274

The Tuberculosis Diagnostics Market was valued at USD 3.01 billion in 2023, expected to reach USD 3.17 billion in 2024, and is projected to grow at a CAGR of 5.48%, to USD 4.38 billion by 2030.

The scope of Tuberculosis (TB) Diagnostics encompasses various tests and procedures aimed at identifying Mycobacterium tuberculosis infection. This includes traditional methods like sputum microscopy, culture tests, and newer molecular diagnostics such as nucleic acid amplification tests (NAATs). The necessity for effective TB diagnostics is underscored by the global burden of tuberculosis, which remains a leading cause of death from an infectious disease. Applications stretch from initial diagnosis and monitoring of treatment response to drug susceptibility testing. End-use sectors include hospitals, diagnostic laboratories, and research institutions, emphasizing both clinical and public health perspectives.

KEY MARKET STATISTICS
Base Year [2023] USD 3.01 billion
Estimated Year [2024] USD 3.17 billion
Forecast Year [2030] USD 4.38 billion
CAGR (%) 5.48%

Market insights reveal that technological advancements, rising TB prevalence, and improved healthcare infrastructure are primary growth influencers. Particularly, the rapid switch to molecular diagnostics is spurred by their higher accuracy and faster results compared to conventional methods. Potential opportunities lie in emerging economies where TB prevalence is high but diagnostic facilities remain limited. There, partnerships with government health initiatives could expand market reach. However, high costs associated with advanced diagnostics, varied accuracy across different TB strains, and limited awareness in low-income regions pose significant challenges.

Innovation areas ripe for exploration include the development of cost-effective, point-of-care diagnostic tools that offer rapid and reliable results. These could revolutionize TB diagnostics, especially in rural and resource-constrained settings. Moreover, research into drug-resistant TB detection methods could provide essential breakthroughs in combating multi-drug resistant tuberculosis.

As the market predominantly displays a fragmented nature due to numerous local and international players, businesses can succeed by investing in product differentiation and strategic collaborations. Collaboration with NGOs and public health programs can enhance market penetration and outreach efforts. Identifying these drivers and addressing the limitations through targeted research and strategic planning can lead to sustained growth in the tuberculosis diagnostics market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Tuberculosis Diagnostics Market

The Tuberculosis Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing burden of tuberculosis globally and need to diagnose at very early stage
    • Increasing R&D investments and intensive diagnostics products in pipelines
    • Supportive government initiatives and rising awareness in the emerging markets
  • Market Restraints
    • High costs associated with tuberculosis diagnostics
    • Limited reimbursement options
  • Market Opportunities
    • Rising number of government awareness programs
    • Advancement in the diagnostics procedures
  • Market Challenges
    • Low coverage or absence of insurance in emerging markets

Porter's Five Forces: A Strategic Tool for Navigating the Tuberculosis Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Tuberculosis Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Tuberculosis Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Tuberculosis Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Tuberculosis Diagnostics Market

A detailed market share analysis in the Tuberculosis Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Tuberculosis Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Tuberculosis Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Tuberculosis Diagnostics Market

A strategic analysis of the Tuberculosis Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Tuberculosis Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ACON Laboratories, Inc., Becton, Dickinson, and Company, bioMerieux SA, Bruker Corporation, Cepheid, Elisabeth Pharmacon, spol. s r.o., ELITech Group, F. Hoffmann-La Roche AG, Hologic Corporation, OSANG HEALTHCARE CO., LTD, PerkinElmer, Inc., Siemens AG, Thermo Fisher Scientific, Inc., and Turklab A.S..

Market Segmentation & Coverage

This research report categorizes the Tuberculosis Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Test Type, market is studied across Drug-susceptibility Testing, Laboratory Methods, Mantoux Test, Nucleic Acid Testing, and Radiographic Methods.
  • Based on Type, market is studied across Point-of-Care Technologies and Rapid Test.
  • Based on End_User, market is studied across Diagnostics Research Laboratory and Hospital & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing burden of tuberculosis globally and need to diagnose at very early stage
      • 5.1.1.2. Increasing R&D investments and intensive diagnostics products in pipelines
      • 5.1.1.3. Supportive government initiatives and rising awareness in the emerging markets
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with tuberculosis diagnostics
      • 5.1.2.2. Limited reimbursement options
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising number of government awareness programs
      • 5.1.3.2. Advancement in the diagnostics procedures
    • 5.1.4. Challenges
      • 5.1.4.1. Low coverage or absence of insurance in emerging markets
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Tuberculosis Diagnostics Market, by Test Type

  • 6.1. Introduction
  • 6.2. Drug-susceptibility Testing
  • 6.3. Laboratory Methods
  • 6.4. Mantoux Test
  • 6.5. Nucleic Acid Testing
  • 6.6. Radiographic Methods

7. Tuberculosis Diagnostics Market, by Type

  • 7.1. Introduction
  • 7.2. Point-of-Care Technologies
  • 7.3. Rapid Test

8. Tuberculosis Diagnostics Market, by End_User

  • 8.1. Introduction
  • 8.2. Diagnostics Research Laboratory
  • 8.3. Hospital & Clinics

9. Americas Tuberculosis Diagnostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Tuberculosis Diagnostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Tuberculosis Diagnostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. ACON Laboratories, Inc.
  • 3. Becton, Dickinson, and Company
  • 4. bioMerieux SA
  • 5. Bruker Corporation
  • 6. Cepheid
  • 7. Elisabeth Pharmacon, spol. s r.o.
  • 8. ELITech Group
  • 9. F. Hoffmann-La Roche AG
  • 10. Hologic Corporation
  • 11. OSANG HEALTHCARE CO., LTD
  • 12. PerkinElmer, Inc.
  • 13. Siemens AG
  • 14. Thermo Fisher Scientific, Inc.
  • 15. Turklab A.S.

LIST OF FIGURES

  • FIGURE 1. TUBERCULOSIS DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. TUBERCULOSIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. TUBERCULOSIS DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. TUBERCULOSIS DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. TUBERCULOSIS DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DRUG-SUSCEPTIBILITY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY LABORATORY METHODS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY MANTOUX TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY RADIOGRAPHIC METHODS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY RAPID TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY DIAGNOSTICS RESEARCH LABORATORY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY HOSPITAL & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM TUBERCULOSIS DIAGNOSTICS MARKET SIZE, BY END_USER, 2018-2030 (USD MILLION)
  • TABLE 146. TUBERCULOSIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. TUBERCULOSIS DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023